Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Group Design02:01

Group Design

The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between the two are due to...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stratification of randomization is not required for a pre-specified subgroup analysis.

Pharmaceutical statistics·2013
Same author

Tumor burden modeling versus progression-free survival for phase II decision making.

Clinical cancer research : an official journal of the American Association for Cancer Research·2012
Same author

Inefficiency of randomization methods that balance on stratum margins and improvements with permuted blocks and a sequential method.

Statistics in medicine·2012
Same author

Analysis of tumor burden versus progression-free survival for Phase II decision making.

Contemporary clinical trials·2011
Same author

Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2010
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Dynamic randomization and a randomization model for clinical trials data.

Lee D Kaiser1

  • 1Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. lkaiser@gene.com

Statistics in Medicine
|July 6, 2012
PubMed
Summary
This summary is machine-generated.

Randomization models validate clinical trial linear analyses. A new model supports arbitrary methods, but requires constant patient treatment probability to avoid biased treatment effect estimation.

Related Experiment Videos

Last Updated: May 20, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Statistical Inference

Background:

  • Linear model analyses are common in clinical trials.
  • Randomization, particularly permuted-block randomization, supports the validity of these analyses.
  • Existing models may not cover all randomization methodologies.

Purpose of the Study:

  • To develop a general randomization model for clinical trial data.
  • To provide valid treatment effect and standard error estimators from a randomization perspective.
  • To derive a central limit theorem for the treatment effect estimator.

Main Methods:

  • Development of a general randomization model applicable to arbitrary randomization methodologies.
  • Derivation of a central limit theorem for the treatment effect estimator.
  • Analysis of the impact of the constant probability condition on estimator validity.

Main Results:

  • The developed randomization model provides valid estimators for arbitrary randomization.
  • Linear model analysis results approximate randomization model results when unit effects lack temporal patterns.
  • Violation of the constant unconditional probability of treatment assignment leads to biased treatment effect estimation.

Conclusions:

  • The new randomization model enhances the validity of linear model analyses in clinical trials.
  • Randomization methods must ensure a constant probability of treatment assignment for unbiased inference.
  • Dynamic randomization methods for unbalanced allocation (e.g., 2:1) that violate this condition should be avoided.